PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 12:00 PM CET
Feedback
Settings

Settings

Goto Application

821,939 results
Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 82,194
1.WO/2022/011752VONOPRAZAN SALT, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 20.01.2022
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
 Appl.No PCT/CN2020/106149 Applicant HINYE PHARMACEUTICAL CO., LTD Inventor LIU, Junhua
Disclosed are a Vonoprazan salt, a preparation method therefor, and use thereof. The Vonoprazan salt of the present invention is a salt formed by Vonoprazan and a complex of an organic acid and bismuth. The present invention also covers a preparation method for the Vonoprazan salt and an application of the Vonoprazan salt in preparation of drugs for treating gastric acid diseases. Compared with existing Vonoprazan salts, the salt formed by Vonoprazan and the complex of the organic acid and bismuth of the present invention has a number of satisfactory advantages, such as good solubility and stability, increased bioavailability, and synergistically increased efficacy.
2.WO/2022/012622DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
WO - 20.01.2022
Int.Class C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
 Appl.No PCT/CN2021/106482 Applicant BEIGENE, LTD. Inventor LEI, Bailin
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
3.WO/2022/013312PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS
WO - 20.01.2022
Int.Class C07D 498/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No PCT/EP2021/069657 Applicant CHIESI FARMACEUTICI S.P.A. Inventor PALA, Daniele
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
4.WO/2022/013417PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS
WO - 20.01.2022
Int.Class C07D 213/75
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
72Nitrogen atoms
75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
 Appl.No PCT/EP2021/069942 Applicant SYNGENTA CROP PROTECTION AG Inventor SIKERVAR, Vikas
Compounds of the formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and to the use of the compounds or compositions in agriculture or horticulture for combating, preventing or controlling animal pests, including arthropods and in particular insects, moluscs, nematodes or representatives of the order Acarina.
5.WO/2022/014857NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME
WO - 20.01.2022
Int.Class C07D 405/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
 Appl.No PCT/KR2021/006773 Applicant LG CHEM, LTD. Inventor CHA, Yongbum
The present invention provides a novel compound and an organic light-emitting element comprising same.
6.WO/2022/012456NOVEL HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
WO - 20.01.2022
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
 Appl.No PCT/CN2021/105686 Applicant CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. Inventor FANG, Haiquan
Provided are heterocyclic compounds of formula (I) as bromodomain and extraterminal (BET) inhibitors, pharmaceutical compositions comprising the compounds, their synthesis and their use for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.
7.WO/2022/013311PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS
WO - 20.01.2022
Int.Class C07D 498/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
498Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No PCT/EP2021/069656 Applicant CHIESI FARMACEUTICI S.P.A. Inventor PALA, Daniele
PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
8.WO/2022/014646AMINEIMIDE COMPOUND, AMINEIMIDE COMPOSITION, CURING AGENT, EPOXY RESIN COMPOSITION, METHOD FOR PRODUCING AMINEIMIDE COMPOUND, ENCAPSULANT, AND ADHESIVE
WO - 20.01.2022
Int.Class C07D 295/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
295Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
22with hetero atoms directly attached to ring nitrogen atoms
28Nitrogen atoms
32acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
 Appl.No PCT/JP2021/026500 Applicant ASAHI KASEI KABUSHIKI KAISHA Inventor KAMIMURA, Naoya
Provided is an amineimide compound having excellent permeability, excellent curability, and storage stability. An amineimide compound represented by formula (1), (2), or (3). (In formulae (1)-(3), R1s each independently represent a hydrogen atom, or a monovalent or n-valent C1-15 organic group which may have a hydroxyl group, a carbonyl group, an ester bond, or an ether bond, R2 and R3 each independently represent an unsubstituted or substituted C1-12 alkyl group, aryl group, aralkyl group, or a C7 or less heterocycle in which R2 and R3 are linked, R4s each independently represent a hydrogen atom, or a monovalent or n-valent C1-30 organic group which may contain an oxygen atom, and n represents an integer of 1-3.)
9.WO/2022/014721PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, OPTICAL SENSOR, AND COMPOUND
WO - 20.01.2022
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
 Appl.No PCT/JP2021/027028 Applicant FUJIFILM CORPORATION Inventor KANEKO Kazuhei
The present invention addresses the problem of providing a photoelectric conversion element that has a photoelectric conversion film having superior vapor deposition suitability and exhibits excellent external quantum efficiency with respect to light having any wavelength in a red wavelength range, a green wavelength range, and a blue wavelength range. Moreover, the present invention also addresses the problem of providing an imaging element, an optical sensor, and a compound, which relate to said photoelectric conversion element.　A photoelectric conversion element according to the present invention has a conductive film, a photoelectric conversion film, and a transparent conductive film in this order, the photoelectric conversion film containing a compound represented by formula (1).
10.WO/2022/015051ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASE
WO - 20.01.2022
Int.Class C07D 413/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
14containing three or more hetero rings
 Appl.No PCT/KR2021/009049 Applicant VORONOIBIO CO., LTD. Inventor JO, Seohyun
The present invention relates to an aryl or heteroaryl derivative and a pharmaceutical composition comprising same as an active ingredient for treatment of kinase-related disease. An aryl or heteroaryl derivative provided according to an aspect of the present invention exhibits an excellent inhibitory activity against kinases, especially receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and as such, can be used as a therapeutic agent for RIPK1-related disease.
# -